MetaCap

Anavex Life Sciences (AVXL) vs ImageneBio (IMA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ImageneBio (IMA) has outperformed Anavex Life Sciences (AVXL) over the past year, losing 44.9% versus a loss of 81.9%. Over five years, AVXL leads with a -97.0% price change compared with -97.9% for IMA. Anavex Life Sciences is the larger company by market cap ($54.8 million vs $48.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVXL-81.86%IMA-44.87%
+70%-10%-89%
Nov 21, 20251 yearNov 20, 2026
AVXL-97.08%IMA-97.89%
+5%-49%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVXL versus IMA key metrics
MetricAVXLIMA
Share price$0.5915$3.92
Market cap$54.83M$48.83M
1-day change-11.39%0.00%
YTD return-83.38%-43.19%
1-year return-81.86%-44.87%
5-year return-96.96%-97.86%
EPS (TTM)$-0.14$-2.11
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$800.00K
Revenue growth (YoY)—-77.14%
Net income (latest FY)$-46.38M$-45.35M
Operating margin—-6056.38%
Net margin—-5668.63%
52-week high$5.36$7.60
52-week low$0.59$3.00
Distance from 52-week high-88.96%-48.42%
Analyst consensusnonenone
Avg. price target upside—+359.18%
Average volume1.15M15.86K
Shares outstanding92.70M12.46M
Employees3418
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IMA has outperformed AVXL by 37.0 percentage points over the past year.

About Anavex Life Sciences

AVXL stock →

Anavex Life Sciences Corp. operates as a biopharmaceutical company.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees

About ImageneBio

IMA stock →

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

AVXL vs IMA FAQ

Which is bigger, Anavex Life Sciences or ImageneBio?

Anavex Life Sciences (AVXL) is larger, with a market capitalization of $54.83M compared with $48.83M for ImageneBio (IMA).

Which stock has performed better over the past year, AVXL or IMA?

IMA returned -44.87% over the past 12 months, compared with -81.86% for AVXL (price return, excluding dividends). Past performance does not predict future results.

Are Anavex Life Sciences and ImageneBio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons